Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2017 / Apr / Li Detector
Neurology Neurology Screening and monitoring Cytology Precision medicine Technology and innovation Research and Innovations

Li Detector

Determining the effectiveness of lithium therapy in bipolar disorder by observing neurons

By Michael Schubert 04/21/2017 1 min read

Share

Patients with bipolar disorder often face years of difficulty before receiving an accurate diagnosis. And that’s not even the end of it. Lithium – the best-known and most thoroughly researched treatment for bipolar disorder – is only effective in about 30 percent of patients. The rest? Diagnosis and treatment initiation can mean up to a year of waiting before being switched to a different treatment method.

Believing that a year is too long to wait, especially with such a stressful disorder, senior author Rusty Gage and his team of researchers wanted to find a way to predict those patients most likely to respond to lithium treatment. The test builds upon previous work that highlighted the hyperexcitability of neurons from patients with bipolar disorder; notably, some neurons were calmed by maintenance in a lithium-containing medium, whereas others were not (1). But obtaining neurons from each patient with the disorder would be impractical in the extreme – so the researchers reprogrammed immune cells from bipolar disorder patients to generate lymphocyte-derived neurons (2). The newly derived cells exhibited the same hyperexcitability, but they also held another secret: two very different electrophysiological patterns – one for lithium responders and another for non-responders. Hoping that the patterns could predict the potential for response in new patients, the researchers trained a computer program on 450 total neurons, using five patients as a teaching set and the sixth as a test of the program’s ability to classify a patient. The result? A system that could identify lithium-therapy responsiveness with 92 percent accuracy.

Credit: Salk Institute. Neurons from two patients with bipolar disorder. Left: lithium responder; right: non-responder.

David Panchision oversees a National Institute for Mental Health program that supports the work. Highlighting the fact that most such experiments use cells from only two or three patients, he stated (3), “The fact that Gage’s group can replicate the hyperexcitability characteristic in neurons from additional bipolar disorder patients is very important. Findings like these are needed to utilize these cells to develop new drugs to treat mental illnesses.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. J Mertens et al., “Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder”, Nature, 527, 95–99 (2015). PMID: 26524527. S Stern et al., “Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients’ responsiveness to lithium”, Mol Psychiatry, [Epub ahead of print] (2017). PMID: 28242870. The Salk Institute, “New method predicts who will respond to lithium therapy” (2017). Available at: http://bit.ly/2pvV3E3. Accessed April 18, 2017.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Shapeshifting Cancer
Neurology
The Shapeshifting Cancer

February 24, 2022

1 min read

Understanding the heterogeneity and plasticity of glioblastoma

Image of the Month
Neurology
Image of the Month

October 21, 2016

1 min read

Who Will Be The Caretakers?
Neurology
Who Will Be The Caretakers?

August 4, 2022

3 min read

Recent allegations of image manipulation in a major Alzheimer’s disease paper reaffirm the importance of research integrity

Getting to the Genetic Core of Autism
Neurology
Getting to the Genetic Core of Autism

August 15, 2022

2 min read

Investigating the genotype-phenotype relationship in autism to improve our understanding of heterogeneity

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.